NCT00374426

Preventing Depression Recurrence in Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 262 (planned)
• Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes. The study will also determine whether depressed diabetic patients who have successfully responded to sertraline (Zoloft) are more likely to have depression recur if the sertraline (Zoloft) is discontinued.

Detailed description

Part A: Prevention of Depression Recurrence in Diabetes 1. To determine the efficacy of maintenance antidepressant medication in preventing or delaying recur-rence of major depression in diabetes. 2. To determine the relationship of sustained depression remission to social, occupational, and global func-tioning, and to quality of life and compliance with diabetes treatment. 3. To determine clinical features predictive of depression recurrence in diabetes. Part B. Longitudinal Study of the Interrelationship of Glycemic Control and Depression 1. To determine the effects of depression remission and recurrence on glycemic control. 2. To determine the efficacy of maintenance antidepressant medication in producing sustained benefits in glycemic control. 3. To determine the interrelationship of daily mood with blood glucose and the effect of maintenance treatment on this relationship.

Conditions

• Major Depression
• Diabetes

Interventions

Type	Name	Description
DRUG	sertraline

Timeline

• Start date: 1998-03-01
• Completion: 2004-10-01
• First posted: 2006-09-11
• Last updated: 2010-03-02

Locations

1 site across 1 country: United States